Scolaris Content Display Scolaris Content Display

Injerto de piel y reemplazo tisular para el tratamiento de las úlceras del pie en personas con diabetes

Appendices

Appendix 1. Search strategies

The Cochrane Wounds Specialised Register

#1 ((diabet* NEAR5 (foot or feet or ulcer* or wound* or amputat*))) AND (INREGISTER)
#2 (((skin and graft*) or (pinch and graft*) or (split and thickness) or (full and thickness) or (allograft* or dermagraft* or apligraf* or autograft* or xenograft*) or (tissue NEAR5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*)) or (cultured and keratinocyte*) or (artificial and skin) or (bio‐engineer* and skin) or (bioengineer* and skin) or (replac* and skin) or ( substitut* and skin))) AND (INREGISTER)
#3 #1 AND #2

The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)

#1 MeSH descriptor: [Diabetic Foot] explode all trees
#2 MeSH descriptor: [Foot Ulcer] explode all trees
#3 (diabet* near/3 ulcer*):ti,ab,kw
#4 (diabet* near/3 (foot or feet)):ti,ab,kw
#5 (diabet* near/3 wound*):ti,ab,kw
#6 (diabet* near/3 defect*):ti,ab,kw
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 MeSH descriptor: [Skin Transplantation] explode all trees
#9 (skin next graft* or pinch next graft*):ti,ab,kw
#10 (split next thickness or full next thickness):ti,ab,kw
#11 (allograft* or dermagraft* or apligraf* or autograft* or xenograft*):ti,ab,kw
#12 MeSH descriptor: [Tissue Engineering] explode all trees
#13 MeSH descriptor: [Biocompatible Materials] explode all trees
#14 MeSH descriptor: [Tissue Scaffolds] explode all trees
#15 (tissue near/5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*)):ti,ab,kw
#16 MeSH descriptor: [Keratinocytes] explode all trees
#17 MeSH descriptor: [Cells, Cultured] explode all trees
#18 (cultured near/2 keratinocyte*):ti,ab,kw
#19 MeSH descriptor: [Skin, Artificial] this term only
#20 (artificial near/2 skin):ti,ab,kw
#21 ((bio‐engineer* or bioengineer*) near/2 skin):ti,ab,kw
#22 (skin near/2 (replac* or substitut*)):ti,ab,kw
#23 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 #7 and #23 in Trials

Ovid MEDLINE

1 exp Diabetic Foot/
2 exp Foot Ulcer/
3 (diabet* adj3 ulcer*).tw.
4 (diabet* adj3 (foot or feet)).tw.
5 (diabet* adj3 wound*).tw.
6 (diabet* adj3 defect*).tw.
7 or/1‐6
8 exp Skin Transplantation/
9 (skin graft* or pinch graft*).tw.
10 (split thickness or full thickness).tw.
11 (allograft* or dermagraft* or apligraf* or autograft* or xenograft*).tw.
12 exp Tissue Engineering/
13 exp Biocompatible Materials/
14 exp Tissue Scaffolds/
15 (tissue adj5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*)).tw.
16 exp Keratinocytes/
17 exp Cells, Cultured/
18 (cultured adj2 keratinocyte*).tw.
19 Skin, Artificial/
20 (artificial adj2 skin).tw.
21 ((bio‐engineer* or bioengineer*) adj2 skin).tw.
22 (skin adj2 (replac* or substitut*)).tw.
23 or/8‐22
24 7 and 23
25 randomized controlled trial.pt.
26 controlled clinical trial.pt.
27 randomi?ed.ab.
28 placebo.ab.
29 clinical trials as topic.sh.
30 randomly.ab.
31 trial.ti.
32 or/25‐31
33 exp animals/ not humans.sh.
34 32 not 33
35 24 and 34

Ovid EMBASE

1 diabetic foot/
2 foot ulcer/
3 (diabet* adj3 ulcer*).tw.
4 (diabet* adj3 (foot or feet)).tw.
5 (diabet* adj3 wound*).tw.
6 (diabet* adj3 defect*).tw.
7 or/1‐6 (16213)
8 exp skin transplantation/
9 (skin graft* or pinch graft*).tw.
10 (split thickness or full thickness).tw.
11 (allograft* or dermagraft* or apligraf* or autograft* or xenograft*).tw.
12 tissue engineering/
13 biomaterial/
14 tissue scaffold/
15 (tissue adj5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*)).tw.
16 keratinocyte/
17 exp cell culture/
18 (cultured adj2 keratinocyte*).tw.
19 artificial skin/
20 (artificial adj2 skin).tw.
21 ((bio‐engineer* or bioengineer*) adj2 skin).tw.
22 (skin adj2 (replac* or substitut*)).tw.
23 or/8‐22
24 7 and 23
25 Randomized controlled trials/
26 Single‐Blind Method/
27 Double‐Blind Method/
28 Crossover Procedure/
29 (random$ or factorial$ or crossover$ or cross over$ or cross‐over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
30 (doubl$ adj blind$).ti,ab.
31 (singl$ adj blind$).ti,ab.
32 or/25‐31
33 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
34 human/ or human cell/
35 and/33‐34
36 33 not 35
37 32 not 36
38 24 and 37

EBSCO CINAHL

S36 S23 AND S35
S35 S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34
S34 MH "Quantitative Studies"
S33 TI placebo* or AB placebo*
S32 MH "Placebos"
S31 TI random* allocat* or AB random* allocat*
S30 MH "Random Assignment"
S29 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S28 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S27 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S26 TI clinic* N1 trial* or AB clinic* N1 trial*
S25 PT Clinical trial
S24 MH "Clinical Trials+"
S23 S7 AND S22
S22 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
S21 TI ( skin N2 (replac* or substitut*) ) OR AB ( skin N2 (replac* or substitut*) )
S20 TI ( (bio‐engineer* or bioengineer*) N2 skin ) OR AB ( (bio‐engineer* or bioengineer*) N2 skin )
S19 TI artificial N2 skin OR AB artificial N2 skin
S18 (MH "Skin, Artificial")
S17 TI cultured N2 keratinocyte* OR AB cultured N2 keratinocyte*
S16 (MH "Cells, Cultured+")
S15 (MH "Keratinocytes")
S14 TI ( tissue N5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*) ) OR AB ( tissue N5 (engineer* or bio‐engineer* or bioengineer* or scaffold* or replac*) )
S13 (MH "Biocompatible Materials")
S12 (MH "Tissue Engineering")
S11 TI ( allograft* or dermagraft* or apligraf* or autograft* or xenograft* ) OR AB ( allograft* or dermagraft* or apligraf* or autograft* or xenograft* )
S10 TI ( split N1 thickness OR full N1 thickness ) OR AB ( split N1 thickness OR full N1 thickness )
S9 TI ( skin N1 graft* OR pinch N1 graft* ) OR AB ( skin N1 graft* OR pinch N1 graft* )
S8 (MH "Skin Transplantation")
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6
S6 TI diabet* N3 defect* or AB diabet* N3 defect*
S5 TI diabet* N3 wound* or AB diabet* N3 wound*
S4 TI ( diabet* N3 foot OR diabet* N3 feet ) or AB ( diabet* N3 foot OR diabet* N3 feet )
S3 TI diabet* N3 ulcer* or AB diabet* N3 ulcer*
S2 MH "Foot Ulcer+"
S1 MH "Diabetic Foot"

Appendix 2. Risk of bias

1. Random sequence generation (selection bias)

Low risk of bias

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random‐number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

High risk of bias

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

Unclear

Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.

2. Allocation concealment (selection bias)

Low risk of bias

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.

High risk of bias

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially‐numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear

Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially‐numbered, opaque and sealed.

3. Blinding or masking of participants, personnel and outcome assessment (performance and detection bias)

Low risk of bias

Any one of the following.

  • No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others was unlikely to introduce bias.

High risk of bias

Any one of the following.

  • No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, and the non‐blinding of others was likely to introduce bias.

Unclear

Either of the following.

  • Insufficient information provided to permit a judgement of low or high risk of bias.

  • The study did not address this outcome.

4. Incomplete outcome data

Low risk of bias

Any one of the following.

  • No missing outcome data.

  • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).

  • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes was not enough to have a clinically relevant impact on observed effect size.

  • Missing data have been imputed using appropriate methods.

High risk of bias

Any one of the following.

  • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was enough to induce clinically relevant bias in intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes was enough to induce clinically relevant bias in observed effect size.

  • ‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.

  • Potentially inappropriate application of simple imputation.

Unclear

Either of the following.

  • Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).

  • The study did not address this outcome.

5. Selective outcome reporting

Low risk of bias

Either of the following.

  • The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way.

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

High risk of bias

Any one of the following.

  • Not all of the study’s prespecified primary outcomes have been reported.

  • One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified.

  • One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

  • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis.

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear

Insufficient information provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6. Other sources of potential bias

Low risk of bias

The study appears to be free of other sources of bias.

High risk of bias

There is at least one important risk of bias. For example, the study:

  • Had a potential source of bias related to the specific study design used; or

  • Has been claimed to have been fraudulent; or

  • Had some other problem.

Unclear

There may be a risk of bias, but there is either:

  • Insufficient information to assess whether an important risk of bias exists; or

  • Insufficient rationale or evidence that an identified problem will introduce bias.

Study flow diagram of the number of records identified, included and excluded, and the reasons for exclusion
Figuras y tablas -
Figure 1

Study flow diagram of the number of records identified, included and excluded, and the reasons for exclusion

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Funnel plot of comparison: 1 Skin grafts or tissue replacements compared with standard care, outcome: 1.1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Figure 4

Funnel plot of comparison: 1 Skin grafts or tissue replacements compared with standard care, outcome: 1.1 Incidence of complete closure of the foot ulcer.

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Analysis 1.1

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 1 Incidence of complete closure of the foot ulcer.

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 2 Incidence of compete closure of the foot ulcer ‐ sensitivity analysis.
Figuras y tablas -
Analysis 1.2

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 2 Incidence of compete closure of the foot ulcer ‐ sensitivity analysis.

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 3 Incidence of lower limb amputations.
Figuras y tablas -
Analysis 1.3

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 3 Incidence of lower limb amputations.

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 4 Ulcer recurrence.
Figuras y tablas -
Analysis 1.4

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 4 Ulcer recurrence.

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 5 Incidence of infection.
Figuras y tablas -
Analysis 1.5

Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 5 Incidence of infection.

Comparison 2 Meshed skin graft compared with split‐skin graft, Outcome 1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Analysis 2.1

Comparison 2 Meshed skin graft compared with split‐skin graft, Outcome 1 Incidence of complete closure of the foot ulcer.

Comparison 3 Dermagraft® compared with OASIS®, Outcome 1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Analysis 3.1

Comparison 3 Dermagraft® compared with OASIS®, Outcome 1 Incidence of complete closure of the foot ulcer.

Comparison 4 Apligraf® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Analysis 4.1

Comparison 4 Apligraf® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.

Comparison 5 Dermagraft® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.
Figuras y tablas -
Analysis 5.1

Comparison 5 Dermagraft® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.

Summary of findings for the main comparison. Skin grafts and tissue replacements compared to placebo or standard care for treating foot ulcers in people with diabetes

Skin grafts and tissue replacements compared to placebo or standard care for treating foot ulcers in people with diabetes

Patient or population: People with diabetes who have foot ulcers
Intervention: Skin grafts and tissue replacements
Comparison: Standard care

Outcomes

Illustrative comparative risks (95% CI)

Relative effect
(95% CI)

No. of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Standard care

Skin grafts and tissue replacement products

Incidence of complete closure of the ulcer (healing rate)

Follow‐up: 6 to 16 weeks

273 per 1000

423 per 1000 (354 to 504)

RR 1.55 (1.30 to 1.85)

1472
(13 studies)

⊕⊕⊝⊝
LOW

Downgraded to low quality of evidence due to lack of blinding, industry involvement and possible publication bias. Furthermore we found wide confidence intervals for a number of comparisons (imprecision).

Time to complete closure of the ulcer

N/A

N/A

N/A

0

(0 studies)

N/A

Time to compete healing of the ulcer was reported very heterogeneously. The majority of studies did not used survival analysis and reported hazard ratios, so meta‐analysis was not possible for this outcome and grading the quality of the evidence was not applicable

Total incidence of lower limb amputations

Follow‐up: 12 weeks

109 per 1000

47 per 1000 (25 to 89)

RR 0.43 (0.23 – 0.81)

522
(2 studies)

⊕⊝⊝⊝
VERY LOW

Downgraded by three levels because only two studies reported on this outcome (imprecision) and possible publication bias is present. Furthermore, a longer follow‐up period is necessary to estimate the effect more precisely.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; N/A: not applicable

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Figuras y tablas -
Summary of findings for the main comparison. Skin grafts and tissue replacements compared to placebo or standard care for treating foot ulcers in people with diabetes
Comparison 1. Skin grafts or tissue replacements compared with standard care

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of complete closure of the foot ulcer Show forest plot

13

1472

Risk Ratio (M‐H, Random, 95% CI)

1.55 [1.30, 1.85]

1.1 Apligraf® or Graftskin®

2

290

Risk Ratio (M‐H, Random, 95% CI)

1.55 [1.17, 2.04]

1.2 Dermagraft®

3

620

Risk Ratio (M‐H, Random, 95% CI)

1.50 [0.85, 2.65]

1.3 EpiFix®

1

25

Risk Ratio (M‐H, Random, 95% CI)

11.08 [1.69, 72.82]

1.4 Graftjacket®

2

114

Risk Ratio (M‐H, Random, 95% CI)

1.90 [0.97, 3.71]

1.5 Hyalograft 3D®

3

324

Risk Ratio (M‐H, Random, 95% CI)

1.57 [1.06, 2.33]

1.6 Kaloderm®

1

59

Risk Ratio (M‐H, Random, 95% CI)

1.32 [0.90, 1.92]

1.7 OrCel®

1

40

Risk Ratio (M‐H, Random, 95% CI)

1.75 [0.61, 5.05]

2 Incidence of compete closure of the foot ulcer ‐ sensitivity analysis Show forest plot

6

614

Risk Ratio (M‐H, Random, 95% CI)

1.49 [1.21, 1.85]

3 Incidence of lower limb amputations Show forest plot

2

522

Risk Difference (M‐H, Random, 95% CI)

‐0.06 [‐0.10, ‐0.01]

3.1 Graftskin®

1

208

Risk Difference (M‐H, Random, 95% CI)

‐0.09 [‐0.18, ‐0.01]

3.2 Dermagraft®

1

314

Risk Difference (M‐H, Random, 95% CI)

‐0.04 [‐0.09, 0.01]

4 Ulcer recurrence Show forest plot

4

276

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.22, 2.22]

4.1 Apligraf® or Graftskin®

2

233

Risk Ratio (M‐H, Random, 95% CI)

0.65 [0.18, 2.35]

4.2 Dermagraft®

1

12

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

4.3 Kaloderm®

1

31

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.06, 13.68]

5 Incidence of infection Show forest plot

9

845

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.53, 0.98]

5.1 Apligraf® or Graftskin®

2

280

Risk Ratio (M‐H, Random, 95% CI)

0.87 [0.43, 1.76]

5.2 Dermagraft®

2

270

Risk Ratio (M‐H, Random, 95% CI)

0.61 [0.40, 0.93]

5.3 EpiFix®

1

25

Risk Ratio (M‐H, Random, 95% CI)

0.19 [0.01, 3.52]

5.4 Graftjacket®

1

28

Risk Ratio (M‐H, Random, 95% CI)

0.6 [0.18, 2.04]

5.5 Hyalograf 3D®

1

171

Risk Ratio (M‐H, Random, 95% CI)

1.35 [0.62, 2.90]

5.6 Kaloderm®

1

31

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.12, 3.24]

5.7 OrCel®

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.5 [0.10, 2.43]

Figuras y tablas -
Comparison 1. Skin grafts or tissue replacements compared with standard care
Comparison 2. Meshed skin graft compared with split‐skin graft

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of complete closure of the foot ulcer Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 2. Meshed skin graft compared with split‐skin graft
Comparison 3. Dermagraft® compared with OASIS®

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of complete closure of the foot ulcer Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 3. Dermagraft® compared with OASIS®
Comparison 4. Apligraf® compared with TheraSkin®

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of complete closure of the foot ulcer Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 4. Apligraf® compared with TheraSkin®
Comparison 5. Dermagraft® compared with TheraSkin®

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of complete closure of the foot ulcer Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 5. Dermagraft® compared with TheraSkin®